BIOGEN INC. (BIIB) Latest Company News

Oct 19, 2026, 11:30 UTC
Biogen announced that it will present nephrology portfolio data, including long-term Phase 3 EMPAVELI results and investigational felzartamab presentations, at ASN Kidney Week in Denver from October 22 to 25, 2026.
Source:
- globenewswire.com
Oct 14, 2026, 22:45 UTC
Altay Therapeutics, Inc. closed a US$37 million Series A financing co-led by Sound Bioventures and HealthCap, with proceeds intended to advance DX5057 and support its drug-discovery platform.
Source:
- timminspress.com
- chathamdailynews.ca
Oct 12, 2026, 13:42 UTC
BIOGEN INC. shares rose 2.20% to $230.67 in U.S. trading.
Source:
- s.kabutan.jp
Oct 12, 2026, 12:29 UTC
BIOGEN INC. shares rose 3.66% to $233.98 in after-hours trading.
Source:
- s.kabutan.jp
Oct 2, 2026, 22:00 UTC
McKinney Health debuted its Living Experience Ambassador Programs (L.E.A.P.) patient advocacy offering on Monday.
Source:
- mmm-online.com
Oct 2, 2026, 15:21 UTC
Biogen reported that the safety profile of litifilimab remains stable with no new safety signals identified.
Source:
- finance.sina.cn
Oct 2, 2026, 15:20 UTC
Biogen reported new 52-week Phase 2 data from the ongoing Phase 2/3 AMETHYST study showing rapid and durable efficacy for Litifilimab in cutaneous lupus erythematosus, reinforcing its potential as a first-in-class therapy.
Source:
Sep 17, 2026, 20:15 UTC
Biogen Inc. announced the publication of a prespecified adolescent subgroup analysis of the Phase 3 VALIANT study evaluating EMPAVELI (pegcetacoplan) in the Clinical Journal of the American Society of Nephrology, showing reduction in proteinuria and stabilized kidney function in adolescents with C3G or primary IC-MPGN.
Source:
- globenewswire.com
Sep 16, 2026, 07:44 UTC
Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.
Source:
- nikkei.com
Sep 10, 2026, 06:15 UTC
NICE said it was unable to recommend omaveloxolone for Friedreich's ataxia on the NHS in England after manufacturer Biogen withdrew its evidence submission, but is ready to reopen the assessment if new evidence is submitted.
Source:
- thenorthernecho.co.uk
Aug 26, 2026, 09:31 UTC
Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.
Source:
- nikkei.com
Aug 25, 2026, 23:35 UTC
Veeva Systems announced that Biogen has selected Veeva Vault CRM globally.
Source:
- prnewswire.com
Aug 25, 2026, 14:45 UTC
The Irish Health Service Executive (HSE) approved reimbursement of Biogen's drug Skyclarys for patients with Friedrich's Ataxia, announced on 25 August 2026.
Source:
- finegael.ie
- corkindependent.com
Aug 6, 2026, 22:15 UTC
Biogen Inc. completed its acquisition of RayThera Inc., a privately held biotechnology company focused on immunology therapies.
Source:
- globenewswire.com
- globenewswire.com
Aug 1, 2026, 08:21 UTC
Amundi increased its stake in Biogen Inc. by 38.2% during the first quarter, acquiring an additional 218,398 shares, as disclosed in a recent SEC filing.
Source:
- defenseworld.net
Jul 29, 2026, 10:00 UTC
Biogen reported second-quarter revenue of $2.74 billion, beating market expectations of $2.47 billion.
Source:
Jul 15, 2026, 15:55 UTC
Biogen presented detailed phase II study data for its Alzheimer's drug diranersen, reaffirming a setback, and announced plans to advance the drug into phase III trials despite missed goals.
Source:
- zacks.com
- reuters.com
Jul 14, 2026, 02:23 UTC
Eisai and Biogen received FDA approval for a subcutaneous injection version of Alzheimer's drug lecanemab (Leqembi) for use in early treatment, with a US launch planned for late August 2026.
Source:
Jun 26, 2026, 13:56 UTC
Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.
Source:
- fiercebiotech.com
- reuters.com
Jun 17, 2026, 22:59 UTC
Biogen Inc. agreed to acquire RayThera Inc. for up to $1 billion.
Source:
Jun 5, 2026, 00:00 UTC
AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.
Jun 4, 2026, 11:30 UTC
Biogen Inc. received FDA Breakthrough Therapy Designation for its drug salanersen for spinal muscular atrophy.
Source:
Jun 3, 2026, 11:30 UTC
Biogen Inc. announced that fourteen abstracts on its nephrology portfolio, including EMPAVELI and felzartamab, were accepted for presentation at the ERA and ATC congresses.
Source:
- globenewswire.com

BIIB

Biogen announced that it will present nephrology portfolio data, including long-term Phase 3 EMPAVELI results and investigational felzartamab presentations, at ASN Kidney Week in Denver from October 22 to 25, 2026.

Altay Therapeutics, Inc. closed a US$37 million Series A financing co-led by Sound Bioventures and HealthCap, with proceeds intended to advance DX5057 and support its drug-discovery platform.

BIOGEN INC. shares rose 2.20% to $230.67 in U.S. trading.

BIOGEN INC. shares rose 3.66% to $233.98 in after-hours trading.

McKinney Health debuted its Living Experience Ambassador Programs (L.E.A.P.) patient advocacy offering on Monday.

Biogen reported that the safety profile of litifilimab remains stable with no new safety signals identified.

Biogen reported new 52-week Phase 2 data from the ongoing Phase 2/3 AMETHYST study showing rapid and durable efficacy for Litifilimab in cutaneous lupus erythematosus, reinforcing its potential as a first-in-class therapy.

Eisai and Biogen received Japanese manufacturing and marketing approval for a subcutaneous injection formulation of their Alzheimer's drug lecanemab (brand name Leqembi), which can be administered at home once weekly with a dedicated pen injector.

NICE said it was unable to recommend omaveloxolone for Friedreich's ataxia on the NHS in England after manufacturer Biogen withdrew its evidence submission, but is ready to reopen the assessment if new evidence is submitted.

Japan's Ministry of Health, Labour and Welfare expert panel deliberated on approval of Eisai and Biogen's Alzheimer's drug Leqembi subcutaneous injection formulation, which would allow home administration.

Veeva Systems announced that Biogen has selected Veeva Vault CRM globally.

The Irish Health Service Executive (HSE) approved reimbursement of Biogen's drug Skyclarys for patients with Friedrich's Ataxia, announced on 25 August 2026.

Biogen Inc. completed its acquisition of RayThera Inc., a privately held biotechnology company focused on immunology therapies.

Amundi increased its stake in Biogen Inc. by 38.2% during the first quarter, acquiring an additional 218,398 shares, as disclosed in a recent SEC filing.

Biogen reported second-quarter revenue of $2.74 billion, beating market expectations of $2.47 billion.

Biogen presented detailed phase II study data for its Alzheimer's drug diranersen, reaffirming a setback, and announced plans to advance the drug into phase III trials despite missed goals.

Eisai and Biogen received FDA approval for a subcutaneous injection version of Alzheimer's drug lecanemab (Leqembi) for use in early treatment, with a US launch planned for late August 2026.

Biogen completed its $5.6 billion acquisition of Apellis and is now integrating the biotech by terminating most of Apellis' research programs and eliminating a small number of research roles.

Biogen Inc. agreed to acquire RayThera Inc. for up to $1 billion.

AbCellera Biologics Inc. appointed Victor Sandor as a Director, effective June 1, 2026.

Biogen Inc. received FDA Breakthrough Therapy Designation for its drug salanersen for spinal muscular atrophy.

Biogen Inc. announced that fourteen abstracts on its nephrology portfolio, including EMPAVELI and felzartamab, were accepted for presentation at the ERA and ATC congresses.